Literature DB >> 10431845

Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.

B Davidson1, B Risberg, G Kristensen, G Kvalheim, E Emilsen, A Bjåmer, A Berner.   

Abstract

The detection of malignant cells in pleural, peritoneal, and pericardial fluids of cancer patients marks the presence of metastatic disease and is associated with a grave prognosis. We evaluated five epithelial markers for the detection of cancer cells in 94 fresh pleural, peritoneal and pericardial effusions. Eighty-four of the samples were regarded as adequate for analysis after evaluation of cytological smears, including 61 samples from patients known to have gynaecological neoplasms. The other 23 samples were from patients with various non-gynaecological malignancies or tumours of unknown origin. Our control cases were 10 fallopian tubes not affected by any malignancy and 12 malignant mesotheliomas. Cell blocks from all cases were stained for CA-125, BerEP4, carcinoembryonic antigen (CEA), BG8 (Lewis Y blood antigen), and B72.3 (TAG-72). Fifty-one of 84 cases were diagnosed as malignant or suggestive of malignancy in cytological smears and/or cell block sections. However, staining for epithelial markers highlighted the presence of malignant cells in 7 additional cases. When membrane staining was evaluated, the sensitivity of the markers studied in detecting malignant cells was as follows: CA-125: 88%, BerEP4: 78%, CEA: 26%, BG8: 86%, B72.3: 79%. Membrane positivity for CEA, B72.3 and BerEP4 was not detected in reactive mesothelial cells. However, membranous staining in mesothelial cells was evident in 13% and 31% of cases with the use of BG8 and CA-125, respectively. Weak cytoplasmic staining for CEA was observed in mesothelial cells in 2 cases. When Ber-EP4, B72.3, and BG8 staining results in cancer cells were combined, the following sensitivity levels were observed: BG8+B72.3: 91%; BG8+Ber-EP4: 90%; B72.3+Ber-EP4: 93%; BG8+Ber-EP4+B72.3: 95%. The detection of malignant cells in effusions is facilitated by the use of immunocytochemistry using a wide panel of antibodies. BerEP4 and B72.3 appear to be the best markers when both sensitivity and specificity are considered, followed by BG8, while CEA and CA-125 have a limited role in the detection of metastases from gynaecological tumours owing to the low sensitivity of the former and the low specificity of the latter. Analysis of all staining results should be based on a thorough morphological examination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10431845     DOI: 10.1007/s004280050393

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

1.  Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings.

Authors:  B Risberg; B Davidson; H P Dong; J M Nesland; A Berner
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

2.  Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Authors:  Klaus Pietzner; Ignace Vergote; Armando Santoro; Radoslav Chekerov; Frederik Marmé; Per Rosenberg; Holger Martinius; Hilke Friccius-Quecke; Jalid Sehouli
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

3.  E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions.

Authors:  Dong-Nan He; Hua-Sheng Zhu; Kun-He Zhang; Wen-Jian Jin; Wei-Ming Zhu; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

4.  Use of discard pleural fluid in molecular research.

Authors:  Frederic W Grannis
Journal:  Nat Rev Clin Oncol       Date:  2011-12-13       Impact factor: 66.675

5.  PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.

Authors:  Y Yuan; H P Dong; D A Nymoen; J M Nesland; C Wu; B Davidson
Journal:  Cytopathology       Date:  2011-02       Impact factor: 2.073

6.  Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.

Authors:  Geoffrey Kim; Ben Davidson; Ryan Henning; Junbai Wang; Minshu Yu; Christina Annunziata; Thea Hetland; Elise C Kohn
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

7.  Unusual N-type glycosylation of salivary prolactin-inducible protein (PIP): multiple LewisY epitopes generate highly-fucosylated glycan structures.

Authors:  Alena Wiegandt; Henning N Behnken; Bernd Meyer
Journal:  Glycoconj J       Date:  2018-06-01       Impact factor: 2.916

8.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma.

Authors:  Vered Givant-Horwitz; Ben Davidson; Gregg van de Putte; Hiep Phuc Dong; Iris Goldberg; Sivan Amir; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.